{"filing":{"accession_number":"0001867096-26-000048","cik":"0001867096","ticker":"XERS","company_name":"Xeris Biopharma Holdings, Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"xers-20260629.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000048/xers-20260629.htm"},"events":[{"id":17008,"run_id":15228,"accession_number":"0001867096-26-000048","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.94,"summary":"Xeris Biopharma appointed Dr. Nerissa Kreher to its Board of Directors effective July 1, 2026, expanding the Board from seven to eight members. Concurrent with this appointment, John Shannon was appointed Chairperson and Marla Persky transitioned to Lead Independent Director. Dr. Kreher received initial equity compensation of approximately $450,000.","company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":15296,"accession_number":"0001867096-26-000048","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Nerissa Kreher, M.D., to the Board of Directors effective July 1, 2026, expanding the Board from seven to eight members. While the section also mentions John Shannon's appointment as Chairperson and Marla Persky's transition to Lead Independent Director, the primary focus and substantive disclosure centers on Dr. Kreher's new director appointment, including her extensive background, independence determination, and initial equity compensation of approximately $450,000. This is a material governance event affecting board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:44:32.981081+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15297,"accession_number":"0001867096-26-000048","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Dr. Nerissa Kreher to the Board of Directors effective July 1, 2026, along with related Board leadership changes including CEO John Shannon's appointment as Chair and Marla Persky's transition to Lead Independent Director. While multiple governance changes are announced, the principal disclosed action centers on the appointment of a new director, making exec_appointment the most salient classification. Board composition changes are material to investors' assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:44:32.981081+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15296,"accession_number":"0001867096-26-000048","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Nerissa Kreher, M.D., to the Board of Directors effective July 1, 2026, expanding the Board from seven to eight members. While the section also mentions John Shannon's appointment as Chairperson and Marla Persky's transition to Lead Independent Director, the primary focus and substantive disclosure centers on Dr. Kreher's new director appointment, including her extensive background, independence determination, and initial equity compensation of approximately $450,000. This is a material governance event affecting board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:44:32.981081+00:00","company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","filing_date":"2026-06-30"},{"id":15297,"accession_number":"0001867096-26-000048","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Dr. Nerissa Kreher to the Board of Directors effective July 1, 2026, along with related Board leadership changes including CEO John Shannon's appointment as Chair and Marla Persky's transition to Lead Independent Director. While multiple governance changes are announced, the principal disclosed action centers on the appointment of a new director, making exec_appointment the most salient classification. Board composition changes are material to investors' assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:44:32.981081+00:00","company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","filing_date":"2026-06-30"}]}